Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod
Immunophenotyping, Microbiome, Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients with High-grade Cervical Intraepithelial Lesions Treated with Imiquimod
Barretos Cancer Hospital
96 participants
Apr 2, 2024
INTERVENTIONAL
Summary
The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients.
Eligibility
Inclusion Criteria5
- Patients between 25 and 45 years of age (reproductive age);
- High-risk HPV carriers;
- Residents less than 300 km from the city of Barretos-São Paulo;
- With a histological diagnosis of high-grade cervical squamous intraepithelial lesion (CIN 3), obtained through colposcopy-guided biopsy performed at the Barretos Cancer Hospital (HCB);
- Acceptance of the Informed Consent Form.
Exclusion Criteria6
- Suspicion of invasive squamous cell carcinoma or Adenocarcinoma (in situ or invasive) by colposcopy and/or cytology;
- Pregnant or breastfeeding;
- Immunodeficiency condition;
- Previous treatment for high-grade cervical squamous intraepithelial lesion;
- Who have been immunized for HPV;
- Have used antibiotics in the last 30 days
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.
Active comparator group will be treated with LEEP.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06356012